Format

Send to

Choose Destination
See comment in PubMed Commons below
Biol Psychiatry. 2009 Apr 1;65(7):550-5. doi: 10.1016/j.biopsych.2008.10.014. Epub 2008 Nov 20.

Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study.

Author information

1
Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK. srchamb@gmail.com

Abstract

BACKGROUND:

Atomoxetine, a selective noradrenaline reuptake inhibitor (SNRI) licensed for the treatment of attention-deficit/hyperactivity disorder (ADHD), has been shown to improve response inhibition in animals, healthy volunteers, and adult patients. However, the mechanisms by which atomoxetine improves inhibitory control have yet to be determined.

METHODS:

The effects of atomoxetine (40 mg) were measured with a stop-signal functional magnetic resonance imaging (fMRI) paradigm in 19 healthy volunteers, in a within-subject, double-blind, placebo-controlled design.

RESULTS:

Atomoxetine improved inhibitory control and increased activation in the right inferior frontal gyrus when volunteers attempted to inhibit their responses (irrespective of success). Plasma levels of drug correlated significantly with right inferior frontal gyrus activation only during successful inhibition.

CONCLUSIONS:

These results show that atomoxetine exerts its beneficial effects on inhibitory control via modulation of right inferior frontal function, with implications for understanding and treating inhibitory dysfunction of ADHD and other disorders.

PMID:
19026407
DOI:
10.1016/j.biopsych.2008.10.014
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center